Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.
about
The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemiaOptimal lipid modification: the rationale for combination therapyFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewThe target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia.Ezetimibe-associated immune thrombocytopenia.Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemiaDyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal.Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.Management of dyslipidemia in women in the post-hormone therapy era.The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level.Treating dyslipidemic patients with lipid-modifying and combination therapies.Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.Ezetimibe for management of hypercholesterolemia.Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice.What's new in lipid management?Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver diseaseNew drugs for the treatment of hypercholesterolaemia.New lipid-lowering agents.Lipid-lowering therapy. New and established agents reduce risk of cardiovascular events.Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans.Lipid-lowering therapies in development.Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood.Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.Model-based development of gemcabene, a new lipid-altering agent.Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On StThe clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice.
P2860
Q24805607-77E01CA0-739B-4615-B931-7D787B28A99EQ28219266-29E4423E-0EEF-428B-9ED3-FE83C2552F48Q28220294-441A3435-9B25-4543-B4AC-674FCD614000Q28573173-8DBBDBF4-2770-4913-BE2C-395F22E0D5BDQ33241121-33761F09-E11B-4A73-998D-DE2EED4F150DQ33367390-5E54B56A-94CE-45E0-9415-513A8F001DBDQ33378549-52644911-F2E3-469B-A025-880CB315707EQ33577611-9F517B2B-7A3F-4A60-942D-03DEFFCDC639Q34049469-6A3B71D8-DA7A-434F-B391-58915D8E82FBQ34079102-A30214A1-CCE0-40D0-B8F3-8227BF10647FQ34357416-6150BFDB-BFDA-402A-8BD1-6EFBC5EA1E1CQ34377352-0976ADF8-2119-4DF5-8A24-FF788B6B7C64Q34674336-3DD5B52C-D633-4EB5-8CE2-5054465FE62FQ34722828-B4F87038-210E-4942-B01A-C56E6C16FCE9Q35080633-FB7C5BCB-9B35-4981-85D0-B3684C7326A6Q35125390-B4282CE1-59F5-4636-A7A6-6E5A30FF7072Q35129072-39D1C5E5-A884-4BD0-9445-912D5DB00D1AQ35139242-C89590E6-C212-4A1C-88A7-2D68EE7F31F3Q35183108-05A8EF6A-69A8-4AE6-9439-5A48323672E5Q35269224-9A07A949-B6F9-40D2-9AE7-69CA831E78C3Q35549738-3C69DCA2-DADC-4AF5-98ED-80194973DE7DQ35550630-DD6D26AB-D6D1-49E7-81AC-DC2444882F24Q35570944-3B0F2F80-C3C4-46B3-A708-27ED735AEE7AQ35602647-E64ACDE9-B2CD-45D0-946E-B5124E6A9455Q35706642-BF236F29-D9FF-4321-8978-437D2C7368EAQ35804027-4F4946E5-CC71-482D-B249-522E5F394BDFQ35832477-90FC3987-63F0-415C-9DDB-EE445DE9F0CCQ35925570-E3017D90-EB9C-47F5-9993-AEEF9CE26EF0Q35958460-4DB04D02-22E8-49B5-AD5E-9E9094DFB67AQ36040720-9FAA2FE2-D6DF-40EC-B3D7-2A26D825682DQ36302709-F6771E74-1596-4D13-BA4E-E4C42CE7EDC4Q36341650-46F00CC4-48D6-4DC3-9CD6-B82DFF9BE0D2Q36569771-C634D53E-CA34-4683-93A5-8C2B30F9C043Q36653658-B9ABDB88-12B5-4552-B155-23B8F3D1B697Q36729113-674CD5C0-590E-4818-BDEE-8B5D590D9857Q36835839-DB62B501-89B5-4A08-8CE3-71169FC428A2Q36847314-740CD038-6D5C-4228-846F-BA5D916F1504Q36940565-761D97B4-8CFA-4778-B87E-2E80197F3AB8Q36943340-03BF08EA-334F-452E-A5A2-0A357E839CAFQ36956106-028FFC2C-A021-4487-BED2-6F4E46713D3A
P2860
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Effectiveness and tolerability ...... lysis of two phase II studies.
@en
Effectiveness and tolerability ...... lysis of two phase II studies.
@nl
type
label
Effectiveness and tolerability ...... lysis of two phase II studies.
@en
Effectiveness and tolerability ...... lysis of two phase II studies.
@nl
prefLabel
Effectiveness and tolerability ...... lysis of two phase II studies.
@en
Effectiveness and tolerability ...... lysis of two phase II studies.
@nl
P2093
P1476
Effectiveness and tolerability ...... lysis of two phase II studies.
@en
P2093
A P Lebeaut
C A Dujovne
C Cuffie-Jackson
E P Veltri
Ezetimibe Study Group
L E Mellars
M A Drehobl
P304
P356
10.1016/S0149-2918(01)80102-8
P577
2001-08-01T00:00:00Z